
Policy Recommendations for Strengthening the Accelerated Approval Program for Oncology Drugs
Memo: Delivered to the U.S. Food and Drug Administration (FDA)
Population Health
Policy
On December 18, 2024, LDI Senior Fellow Sean Hennessy, PharmD, PhD submitted a comment in response to a Request for Comments from the U.S Food and Drug Administration and U.S. Department of Health and Human Services. The request sought input regarding methodological challenges related to data on patient experience.
As an expert in pharmacoepidemiology, the study of the health effects of drugs and other medical products in populations, Dr. Hennessy provides 10 suggestions for improving the use of patient experience data in patient focused drug development.
Memo: Delivered to the U.S. Food and Drug Administration (FDA)
Research Memo: Delivered to House Speaker Mike Johnson and Majority Leader John Thune
Research Memo: Delivered to House Speaker Mike Johnson and Majority Leader John Thune
Research Memo: Response to Request for Technical Assistance
Research Memo: Supplement to Response to Request for Technical Assistance
Research Memo: Delivered to Staff of U.S. Senate Committee on Finance